Bracco Imaging S.p.a.

Dibra S.p.a.

Zambon S.p.a.

Blaschim S.p.a.

Bracco Industria Chimica, S.p.a.

Bracco International Bv

Blasinachim S.p.a.

Bracco Chimica S.p.a.

Bracco Industria Chemica S.p.a.

Fulvio Uggeri

Claudio Giordano

Luciano Lattuada

Pier Lucio Anelli

Silvio Aime

Graziano Castaldi

Marino Brocchetta

Pierfrancesco Morosini

Franco Fedeli

Alessandro Maiocchi

Massimo Visigalli

Enzo Terreno

Silvia Cavicchioli

Mario Virtuani

Daniela Delli Castelli

Giovanni Villa

Luciano Fumagalli

Ernst Felder

Giovanni Battista Giovenzana

Christoph De Haen

Aldo Belli

Ornella Gazzotti

Dario Livio Longo

Kondareddiar Ramalingam

Marcella Murru

Giovanna Lux

Giuseppe Manfredi

Michele Serleti

Attilio Citterio

Carlo Scolastico

Roberta Fretta

Leonardo Manzoni

Gabriella Leonardi

Herv&eacute; Tournier

Giorgio Vittadini

Camilla Cavallotti

Daniela Palano

Maurizio Franzini

Aurelia Ferrigato

Milena Gabellini

Daniela Arosio

Evelin Vignale

Carlo Musu

Matteo Galli

Rolf E Swenson

Edmund R Marinelli

Bo Song

Francesco Minisci

Valentina Mainero

Magnus Karlsson

Mathilde H Lerche

Pernille Rose Jensen

Federica Buonsanti

Fabio Tedoldi

Zsolt Baranyai

Luisella Calabi

Andrea Beltrami

Armando Rossello

Elisa Nuti

Giovanni Valbusa

Silvia Ceragioli

Roberta Mazzon

Elisa Battistini

Alessandro Barge

Sergio Paoletti

Luisa Poggi

Francesca Reineri

Chiara Brioschi

Gabriele Meli

Roberto Gobetto

Marco Crosetti

Stanislava Ivanova Avramova

Linda Chaabane

Vito Lorusso

Giorio Vittadini

Ernest Felder

Lino Paleari

Lucio Pier Anelli

Baranyai Zsolt

Ernö Brücher

Letizia Sorti

Alberto Vertova

Simona Bussi

Alessandro Minguzzi

Pierlucio Anelli

Federica Lazzari

Daniela Santelia

Walter Dastru′

Davide Belnome

Carlo Morelli

Joseph Stancanello

Walter Dastrù

Nicol Guidolin

Alessandra Viale

Cristiana Campa

Anna Coslovi

Alfonso Colombatti

Carla Danussi

Pier Francesco Morosini

The invention relates to a process for the preparation of a 2,4,6-triiodo-phenol derivative of formula (II), which is useful as an intermediate for the synthesis of conventional X-ray contrast agents, said process comprising the tri-iodination of the correspondent phenol derivative of said 2,4,6-triiodo-phenol derivative by means of an iodinating system comprising Iand an oxide or a salt of an element of group 11 of the periodic table.

Process for the preparation of 2,4,6-triiodophenol derivatives

The invention is related to a process for preparing a iodinating X-rays contrast agent. More specifically, it relates to a process for the preparation of N,N'-bis-(2,3-dihydroxypropyl)-5-hydroxy-2,4,6-triiodo-1,3-benzenedicarboxaniide (I) by electrochemical iodination of N,N′-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide (II) with molecular iodine (I2) which is in situ electrochemically generated from a source of iodide ions (I−). The iodide ions (I−) are obtained by the dissolution of hydrogen iodide (HI) or an alkali metal iodide in the reaction medium or produced during the reaction of N,N′-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide with I2. The invention also relates to the use of the intermediate compound of formula (I), obtained through the above electrochemical iodination of compound (II), in the preparation of N,N′-bis[2,3-dihydroxypropyl]-5(hydroxyacetyl)methylamino]-2,4,6-triiodo-1,3-benzenedicarboxamide (iomeprol).

Electrochemical iodination of N,N'-(2,3-dihydroxypropyl)-5-hydroxy-1,3-benzenedicarboxamide

The present invention relates to the use of a NIR fluorescent probe comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety in the fluorescence-guided surgery of pathologic regions and to an optical imaging method that comprises using this fluorescent probe for the identification and demarcation of tumor margins during the surgical resection.

Intra-operative imaging

The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable steroisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable steroisomers in solution useful as concentration independent CEST responsive agents.

CEST systems exhibiting a concentration independent responsiveness

The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable stereoisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable stereoisomers in solution useful as concentration independent CEST responsive agents.

The present invention discloses a process for the preparation of gadobenate dimeglumine complex in a solid form. In particular, said solid form is conveniently obtained by spray-drying a corresponding liquid suspension at a given temperature and concentration. The present invention is particularly advantageous for the industrial scale as the solid form may be obtained by employing water as a solvent, which is a non-toxic solvent, easy to handle and basically not requiring troublesome health or safety precautions.

Process for the preparation of gadobenate dimeglumine complex in a solid form

The present invention generally relates to a process for the preparation of aqueous solutions of hyperpolarized molecules ready for use in in-vivo MR diagnostic imaging, the use thereof as MRI contrast agent in investigation methods for producing diagnostic MR images of a human or non-human animal body organ, region or tissue.

Process for preparing hyperpolarized substrates and method for MRI

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R, R, R, G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents. 

Diagnostic agents selective against metalloproteases

The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.

Integrin targeted synthetic ligands for diagnostic and therapeutic applications

The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel peptides able to bind fibrin, to a process for their preparation and to compositions thereof for use in therapy and diagnostics. The compounds of the invention bind, in particular, to fibrin present in the extracellular matrix (EC) of tumor or connective tissue of stroma thus acting as targeting moieties able to bring and successfully bound an active moiety linked thereto to fibrin depositions inside solid tumors.

Fibrin binding peptide conjugates for diagnostic and therapeutic applications

The present invention relates to a process for the preparation of iodinated anilines; in particular, it relates to a process including the direct iodination, with suitably activated iodine, of 3,5-disubstituted anilines to the corresponding 3,5-disubstituted-2,4,6-triiodoanilines, which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves. 

Process for the iodination of aromatic compounds

The present invention relates to a process for the preparation of iodinated phenols, &#x2014;in particular, it relates to a process including the electrochemical iodination of 3,5-disubstituted phenols of formula (1) to the corresponding 3,5-disubstituted-2, 4,6-triiodophenols of formula (2), which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves. Furthermore, the present invention includes the electrochemical iodination of 3, 5- disubstituted anilines of formula (6) to the corresponding 3,5-disubstituted-2,4,6-triiodoanilins of formula (7). 

The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered as a single oral dose comprised from 0.2-20 g.

Use of L-Histidine and derivatives thereof

The invention relates to a one-step process for the preparation of aqueous solutions of hyperpolarized molecules in which, in a single step, the said hyperpolarized molecules are separated from the crude solution by means of a fast phase-transfer extraction and isolated in an impurity-free aqueous solution, ready for use in the MRI diagnostic imaging of organs, region or tissues of the human or animal body.

Process for the preparation of aqueous solutions of hyperpolarized molecules

The present invention relates to a process for the preparation of iodinated phenols; in particular; it relates to a process including the direct iodination, with suitably activated iodine, of 3,5-disubstituted phenol compounds to the corresponding 3,5-disubstituted-2,4,6-triiodophenols, which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves.

Process for the iodination of phenolic derivatives

Growing community of inventors

Codogno, Italy

Fulvio Uggeri